Generally, the aspects of the technology described herein relate to systems and methods of identifying molecules of single-strand DNA (ssDNA) and single-strand RNA (ssRNA), such as a target sequence of nucleotides. Certain aspects relate to detecting the presence of a target sequence in a concentration of nucleic acids using electrophoretic mobility shift of molecular beacons (MBs) and nucleic acids during electrophoresis.
MicroRNA molecules (miRNAs) were first described in the nematode Caenorhabditis elegans in early 1990. These molecules are short, non-coding RNA sequences (19-22 nucleotides (nt)) that primarily function as silencers of RNA expression, and regulators of gene expression. The array of functions of the miRNA-regulated RNA molecules is significant, spanning cell division, growth, differentiation, apoptosis, and migration. The number of confirmed mature miRNAs continues to increase, with their number to date of 1917 precursors, and 2654 mature for Homo sapiens [GRCh38]. More recently, miRNAs have received increased attention for basic biological processes, and as biomarkers in liquid biopsy for disease diagnostics, progression, treatment efficacy and relapse. Quantitative detection of miRNAs in various biological fluids is usually performed using Northern blotting or PCR-based techniques, which are usually laborious and time consuming.
According to one aspect of the present application, a method for detecting one or more nucleic acids comprising a target sequence of nucleotides is provided, the method comprising incubating molecular beacons (MBs) with a concentration of nucleic acids, each nucleic acid comprising a sequence of nucleotides, wherein the molecular beacons are configured to generate a fluorescence signal when bound with the target sequence performing electrophoresis by applying voltage and determining, using the electrophoretic mobility shift of the MBs and nucleic acids during electrophoresis, the presence of the target sequence in the concentration of nucleic acids.
In some embodiments, the target sequence corresponds to a mutated sequence.
In some embodiments, the target sequence is a micro ribonucleic acid (miRNA).
In some embodiments, the target sequence is a single strand ribonucleic acid (ssRNA).
In some embodiments, the target sequence is a single strand deoxyribonucleic acid (ssDNA).
In some embodiments, the method further comprises conjugating the concentration of nucleic acids with streptavidin beads.
In some embodiments, the method further comprises obtaining blood of a patient, isolating ribonucleic acid (RNA) from red blood cells (RBCs) of the blood of the patient.
In some embodiments, a gel used in electrophoresis is not stained.
In some embodiments, electrophoresis comprises applying a first voltage for a first period of time and a second voltage for a second period of time.
In some embodiments, the method further comprises determining a measurement indicative of a quantity of nucleic acids comprising the target sequence.
According to one aspect of the present application, a system is provided, the system comprising at least one computer hardware processor, and at least one non-transitory computer-readable storage medium storing processor-executable instructions that, when executed by the at least one computer hardware processor, cause the at least one computer hardware processor to perform a computer implemented method for performing methods described herein. Some aspects of the present application include at least one non-transitory computer-readable storage medium storing processor-executable instructions that, when executed by at least one processor, cause the at least one processor to perform the above aspects and embodiments. Some aspects include an apparatus having a processing device configured to perform the above aspects and embodiments.
Various aspects and embodiments will be described with reference to the following exemplary and non-limiting figures. It should be appreciated that the figures are not necessarily drawn to scale. Items appearing in multiple figures are indicated by the same or a similar reference number in all the figures in which they appear.
MicroRNAs are short, non-coding RNA sequences (e.g., typically 19-22 nucleotides (nt)) that primarily function as silencers of RNA expression, and regulators of gene expression. The array of functions of the miRNA-regulated RNA molecules is significant, spanning cell division, growth, differentiation, apoptosis, and migration. Quantitative detection of miRNAs in various biological fluids is usually performed using Northern blotting or Polymerase Chain Reaction (PCR)-based techniques. These techniques are usually laborious and time consuming.
To address some of these shortcomings of conventional approaches, the inventors have developed techniques for rapid, and affordable methods for sensitive detection of single-stranded DNA and RNA in point-of-care settings. In particular, the inventors have developed techniques for the use of electrophoretic mobility (e.g., delayed electrophoretic mobility) for detection of target sequences of nucleotides, such as miRNAs, using molecular beacons (MBs).
Molecular beacons (MBs) are hairpin-shaped oligonucleotides (RNA or DNA) that contain an anti-sense hybridization sequence matched to a specific target sequence of nucleotides such as single-stranded RNA or DNA molecule. MBs also include a double-stranded stem region, and at its termini, a fluorochrome and a quencher.
In the absence of the target sequence, the stem sequence keeps the quencher (e.g., 113) and the fluorochrome (e.g., 112) in close proximity preventing the MB from fluorescing. Binding of the MB to the target by the hybridization sequence triggers a conformational change in the stem which opens the beacon and separates the quencher from the fluorochrome, allowing emission of fluorescence upon excitation. Only the binding of the MB with the intended target (e.g., single strand ribonucleic acid (ssRNA) or single strand deoxyribonucleic acid (ssDNA)) should generate a fluorescence signal, although separation of the quencher from the fluorochrome by contaminating ribonucleic acids (RNAses), or temperature-dependent changes in conformation could also have the same results. Using locked nucleic acids (LNA) instead of standard nucleotides when synthesizing the MBs can successfully alleviate this problem. The readouts for the MB-generated signal may involve fluorometry, microscopy, or more recently, when using biotinylated or cell penetrating peptides-conjugated MB, flow cytometry.
More recently, MBs have started to be used successfully not only for the detection of, but also for the differentiation between miRNAs and precursor-miRNAs (pre-miRNA) (the loop sequence) using fluorometry as a readout method. MBs coupled to cell penetrating peptides (CPP) may be used for detection of miRNAs species in both cells and extracellular vesicles using super resolution microscopy and nano flow cytometry. However, the cost of the CPP-MBs and of the necessary microscopes or flow cytometers for detection limits its use in point-of-care settings.
Molecular probes based on DNA self-assembly (referred to herein as DNA nanoswitches) are structures that include, for example, a long ssDNA scaffold (e.g., almost 8000 bps long) that has been titled with complementary oligonucleotides and/or decorated with affinity reagents that can bind to change the topology of the nanoswitch. These changes in topology can be read out using gel electrophoresis due to their effect on electrophoretic mobility. Techniques described herein can be used to demonstrate high-sensitivity, high-specificity detection of protein biomarkers in serum by decorating each nanoswitch with a pair of sandwiching antibodies, in point-of-care (POC) settings. Furthermore, by replacing the antibodies with strands of ssDNA complementary to nucleic acid sequences of interest, this concept has been extended to enable the detection of miRNAs.
Upon hybridization with target sequences (e.g, miRNAs), MBs form a fluorescent duplex with reduced electrophoretic mobility compared to MB alone, thus bypassing the need for additional staining. In addition to emission of light, the location of the fluorescent band on the gel acts as an orthogonal validation of the target identity, further conforming the specificity of binding. According to some embodiments, the limit of detection of this approach is between 10 to 110 pM, depending on the MB sequence. The method may be sensitive enough to detect specific red blood cell miRNAs molecules in total RNA, with single nucleotide specificity, in less than 30 minutes.
One aspect of the present application includes a method for detecting one or more nucleic acids comprising a target sequence of nucleotides, the method comprising incubating molecular beacons (MBs) with a concentration of nucleic acids, each nucleic acid comprising a sequence of nucleotides, wherein the molecular beacons are configured to generate a fluorescence signal when bound with the target sequence, performing electrophoresis by applying voltage, and determining, using the electrophoretic mobility shift of the MBs and nucleic acids during electrophoresis, the presence of the target sequence in the concentration of nucleic acids.
In one aspect of the present application, an electrophoretic-based method is provided which identifies the detection of specific ssRNA and ssDNA molecules, for example, by the coincident output of both delayed electrophoretic mobility and emission of fluorescence. The technology developed by the inventors allows for an approach that does not require any staining, as the signal is provided by the fluorescence of the beacon following the binding to the target ssRNA or ssDNA. Moreover, as the two means of detection are orthogonal (fluorescence and changes in the electrophoretic speed of the single MB compared to the MB-target complex), this adds an additional level of specificity to the method. As no washing or amplification steps are required, it can be used as a sensitive and easy-to-use assay in a laboratory setting or at the point-of-care.
In step 1102, the method includes incubating molecular beacons (MBs) with a concentration of nucleic acids, each nucleic acid comprising a sequence of nucleotides, wherein the molecular beacons are configured to generate a fluorescence signal when bound with the target sequence.
In step 1104, the method includes performing electrophoresis by applying voltage. For example, according to some embodiments, a constant voltage may be applied for a predetermined amount of time. In some embodiments, a first constant voltage may be applied for a first amount of time, and subsequently, a second constant voltage may be applied for a second amount of time, for example, as described herein.
In step 1106, the method 1100 includes determining, using the electrophoretic mobility shift of the MBs and nucleic acids during electrophoresis, the presence of the target sequence in the concentration of nucleic acids. According to some examples, the method may also include determining the presence of the target sequence in the concentration of nucleic acids using a coincident output of both the electrophoretic mobility and emission of fluorescence. According to some examples, the method may also include quantifying an amount of the target sequence in the concentration of nucleic acids using a coincident output of both the electrophoretic mobility and emission of fluorescence.
miRNA-MB Hybridization Detection by Fluorometry
According to some embodiments, the MBs may be diluted prior to incubation. For example, MBs may be diluted in 100 μL of dPBSIX to a final concentration of 50 nM, and then incubated with different concentrations of synthetic miRNA oligonucleotide target analog (from 0 to 50 nM) in 96 well plates (e.g, such as Corning™ 96-Well clear bottom, black walls) for 30 min at 37° C. or 55° C. The fluorescence intensity of each well may then be measured (λEx 495 nm; λEm 521 nm) by a microplate reader (e.g., Synergy HT Multi-Mode, Biotek, Winooski, VT, USA). For the kinetics assay, MBs were diluted in 100 μL of dPBS1X to a final concentration of 50 nM, and then incubated with either 0, 50 nM target analog or 50 nM mismatch sequences in 96 well plates. Fluorescence (λEx 495 nm; λEm 521 nm) was acquired at 55° C. every 5 min using a BioTek Synergy 4 fluorometer.
Prior to conjugation, MBs were diluted to 50 nM in dPBSand heated at 90° C. for 5 minutes, as per manufacturer instructions. Streptavidin beads were diluted in dPBS to a concentration of 10,000 beads/uL. MBs were added to 500 nm streptavidin beads and incubated at 37° C. for 15 min. Once the incubation was completed, the MB-conjugated beads were washed 3 times in 1 mL of dPBS and centrifuged at 5600 xg for 5 min to remove any free MBs. After washing, MB-beads were resuspended to a final volume of 200 uL with a final concentration of 50 nM of synthetic miRNA oligonucleotide target analog. Using flow cytometry, miRNA-MB hybridization was analyzed over a time course (0, 1, 5, 10, 20, and 30 min of incubation at 37° C.), and the efficiency of miRNA-MB hybridization was also determined for different miR-451a mismatch analog sequences (WT, and mutations 1, 2, 3, and 4, see Table 1). Target and mutation analog sequences were incubated at 37° C. for 30 min before analysis.
miRNA-MB Hybridization Detection by Flow Cytometry
As the size of the streptavidin beads was 500 nm, the CytoFLEX LX flow cytometer was set up in the “nanoparticle detection mode” as previously reported. Briefly, within the violet pod, the 450/45 bandpass was placed in position one and the 405/10 bandpass was placed in position two (Detector One). VSSC was used as the trigger parameter, and VSSCA linear versus SSCA log was plotted for bead population determination. The settings were optimized using Polysciences NIST Nanoparticle bead mix with sizes ranging from 80-500 nm, and set as follows: SSC: 58 V, VSSC: 50 V, FITC: 95 V, the FITC channel was used to measure the fluorescein fluorescence of the bead-attached MBs. For consistency, 15,000 events in the 500 nm gate population were recorded for each specimen. Each sample was acquired at a rate of approximately 10,000 events per second.
miRNA-MB Hybridization Detection by Gel Electrophoresis
Twenty microliters of 50 nM MB were incubated with various concentrations of synthetic miRNAs or DNA oligonucleotide target analogs for 30 min, mixed with Gel Loading dye (6X), and then loaded into a Novex TBE 4-20% gels. Gel electrophoresis was performed with constant voltage for 10 min at 100V, and then the voltage was increased to 150V for an additional 40 min. The MB fluorescence signal was visualized using 6-Fluorescein or Alexa 488 channel on a ChemiDoc MP Imaging System (Bio-rad, Hercules, CA). Exposure times were set on “Manual”, and varied depending on the sample between 10 to 300 seconds. The gel electrophoresis kinetic assay was performed by incubating 10 nM MB with 10 nM of synthetic DNA oligonucleotide target analogat various time points (15 seconds, 1, 5, 10, 20, and 30 min). The samples were prepared in a final volume of 20 uL using a 96-well plate, and kept at 370 C. As all the time points had to be run simultaneously, DNA oligonucleotide target analog was added in a staggered order starting with the 30 min time point. After 10 minutes, the target was added to the 20 min time point well, and so forth. One-minute before the 30-minute incubation time expired, the 20 uL in each well were mixed with 4 uL of Gel Loading dye and loaded into the gel. For the “0 min” time point the beacon was mixed with the DNA oligonucleotide target analog, gel Loading dye, and then added directly into the gel. Once loaded, the samples were run at 95V, constant voltage, for 1.5 hours. The gel was imaged as described above.
The current study was approved by the Beth Israel Deaconess Medical Center Institutional Review Board (IRB). Four milliliters of fresh whole blood were obtained via venipuncture using 5 mL of Vacutainer EDTA tubes (BD, Franklin Lakes, NJ) from 5 self-declared healthy volunteers. First, plasma was separated from whole blood by centrifugation of 500 xg for 10 min. RBCs were isolated by diluting the whole blood 1:1 with HBSS——, and passing the blood through an Acrodisc white blood cells (WBC) removal syringe filter (Pall Corporation, NY). RBCs were then washed in 1 mL of HBSS—— three times at 500 xg for 10 min each, to remove any residual platelets.
RNA Isolation, cDNA Synthesis and qPCR
According to some embodiments, the concentration of nucleic acids may include RNA from a patient. In some examples described herein, red blood cells (RBCs) were collected from 5 self-declared healthy donors as described above. RBC small RNA was purified (e.g., using miRNeasy Mini Kit (Qiagen) following manufacturer's protocol). Isolated RNA was quantified using Qubit™ microRNA Assay Kit in a Qubit 4 Fluorometer (Thermo Fisher). Gel bands were cut using a scalpel, and RNA was eluted from gel using MinElute Gel extraction kit (Qiagen). Complementary DNA (cDNA) synthesis was performed using TaqMan Advanced miRNA cDNA Synthesis Kit (Thermo Fisher). Quantitative PCR (qPCR) was performed using TaqMan Fast Advanced Master Mix (Thermo Fisher) in triplicates with the primers hsa-miR451a (Taq Man assay ID 001105), hsa-miR486-5p (TaqMan assay ID 478128_mir), hsa-miR-92a-3p (assay ID, 000431), and hsa-miR16-5p (assay ID, 000391) in a 7500 Fast Real-time PCR System (Applied Biosystems, US.). The qPCR thermal cycling conditions were set as follow: Step 1: Enzyme activation at 95° C. for 20 sec, 1 cycle; Step 2: Denaturing at 95° C. for 3 sec, and anneal/extend at 60° C. for 30 sec, 40 cycles. Analyses of the data (Ct values for each replicate) were performed using the standard curve method, and the threshold baseline was adjusted to 1.7 for all samples.
Linear regression and R-squared values (r2) were used to test linearity between increasing concentrations of MB-target and detected fluorescence. Limit of detection (LOD) was calculated based on area under the curve (AUC) values obtained from 0 nM (background) and 0.1 nM from three independent experiments. AUC from gel bands was measured using ImageJ software (National Institutes of Health, Bethesda, Maryland).
As described herein,
As described herein, in the absence of the target sequence, the stem sequence keeps the quencher (e.g., 113) and the fluorochrome (e.g., 112) in close proximity preventing the MB from fluorescing. Binding of the MB to the target by the hybridization sequence triggers a conformational change in the stem which opens the beacon and separates the quencher from the fluorochrome, allowing emission of fluorescence upon excitation. Only the binding of the MB with the intended target (e.g., single strand ribonucleic acid (ssRNA) or single strand deoxyribonucleic acid (ssDNA)).
In the example of
In
In
In the example of
In the example of
In the example of
In the example of
Below is a description of exemplary materials that may be used in the processes described herein.
Dulbecco's phosphate-buffered saline (dPBS, 2.6 mMKCl, 1.47 mM KH2 PO4, 137 mMNaCl, and 8.05 mM Na2HPO4), Hanks' Balanced Salt Solution (HBSS——, no calcium, no magnesium), Invitrogen Novex TBE Running Buffer (5X), and Novex TBE Gels, 4-20% were obtained from Thermo Fisher Scientific (Waltham, MA). Gel Loading Dye, Purple (6X), no SDS was obtained from New England Biolabs (Ipswich, Massachusetts). Five hundred nanometer Streptavidin beads were purchased from Bangs Laboratories (Fishers, IN). MiRCURY LNA miRNA Inhibitors (antimiRs) were obtained from Qiagen (Germantown, MD).
Molecular beacons and synthetic miRNAs or DNA oligonucleotide target analogs were obtained from Integrated DNA technologies IDT (Coralville, IA). All MBs were conjugated with a 5′ end 6-carboxyfluorescein (λEx 495 nm; λEm 517 nm), and at the 3′ end an internal ZEN quencher, followed by an 18-atom hexa-ethyleneglycol spacer (ISp18), and a biotin. The mutated miRNAs had the following modifications: M1, mutation from C to A in the 10th position; M2, mutation from CC to AA in the 10th and 11th positions; M3, mutation from U to C in the 22nd position (M3); and M4, mutation from UU to CC in the 21stand 22ndposition. All the MBs and corresponding target sequences used for this project are shown in Table 1.
The example of
The experiments represented in
The principle of MB-based nucleic acid detection using gel electrophoresis, relies on: i) a different electrophoretic speed on the MB-target complex vs. miRNA/MB alone, and ii) the binding-dependent fluorescence of the MB (
According to the examples of
As the initial targets used for these experiments were synthesized using a DNA backbone, and the goal was to validate the approach using miRNAs obtained from biologically relevant samples, testing to determine whether the signals obtained from RNA and DNA targets analogs were comparable was performed. The experiments reported in
In the example shown in
Current molecular beacon-based methods for detection of point mutation afford identification of single mutation as long as the mismatched nucleotide is flanked on either side by at least one functional base pair. The ability of the electrophoretic mobility shift to differentiate between the wild type miRNA target analog and several 1 and 2 nt mutated miRNA target analog sequences was tested (
In the examples shown in
As all the results presented above were obtained using synthetic DNA or RNA backbones as miRNA analogs, it was next sought to validate the approach using purified RNA from blood cells, specifically RBCs. Total RNA from RBCs was isolated from 5 self-declared healthy donors and the levels of hsa-miR-451a were measured using both RT-qPCR and gel electrophoresis. For the electrophoretic mobility assay, 100 nM of miR451aMB with increasing amounts (25, 75, 150, and 250 ng) of total RBC RNA were incubated. As a positive control, hsa-miR-451a, and as negative hsa-miR-486-5p inhibitor were used. Similar to the results obtained using synthesized RBC miRNAs, the fluorescence intensity of the miR451aMB-target band increased with the amount of RBC RNA added to the reaction. The positive band did not form when the RNA was pre-incubated with a specific hsa-miR-451a miRCury LNA Inhibitors (anti-miRs). The MB-miR451a hybridization was not affected when incubating the RNA with a hsa-miR-486-5p inhibitor, further confirming the identity of the positive band as the presence of a duplex MB-hsa-miR-451a (
For several decades, fluorometry was the standard method used to quantify the fluorescence triggered by the binding of MB to their target sequences. This method affords, unlike cell-based approaches, a tight control over experimental conditions such as MB and target concentration, buffer pH and composition, ion content, as well as changes in temperature during experiments. Furthermore, this method allows MB fluorophore multiplexing, conjugation of MB with gold nanoparticles or qDots. In addition to the stable and controlled conditions, the frequency of sample interrogation can be set anywhere between seconds to tens of minutes. A drawback of fluorometry is bulk reading of the reaction solution when the presence of free fluorophore, incomplete quenching, and degraded beacon will significantly increase the noise, and decrease the sensitivity.
Methods described herein include a gel electrophoresis-based readout method to detect specific miRNAs in the picomolar range. The built-in on/off fluorescence reporter generates light only when the MB is hybridized with the intended target, circumventing the need for additional staining steps, and due to the delayed electrophoretic mobility of the MB-target duplex, the location of the positive fluorescent band also acts as an orthogonal confirmation of the specificity of target binding.
The gel electrophoresis-based readout is fully applicable to identifying various ssRNA and ssDNA molecules found in biological fluids, such as, viruses, circulating RNA complexes, cell-free DNA, and nucleic acids associated with extracellular vesicles. As certain sequences of interest may not be readily available for MB hybridization due to either secondary structure, or the presence of interacting proteins, incubating the sample with helper oligos, which flank the target site, may also improve the chances for a positive MB signal. For double-stranded nucleic acids, using the direct MB approach as described here is not feasible, unless the selected region is present in a loop of the molecule where the beacon has access, or when using a CRISPR/cas9-MB tandem approach, as was recently reported in living cells.
The sensitivity limit of this approach depends primarily on the brightness of the fluorochromes, the sensitivity of the imaging device, and the autofluorescence of agarose gels. Using quantum dots (qDots) as MB fluorochromes has been used successfully for both, increasing the sensitivity of the signal, and affording longer integration times with limited photobleaching. As the size of qDots is between 2-6 nm this approach should not hinder the migration of the MB or MB-target complex on the gel. For transcripts longer than miRNAs, using several MB and FRET MB tandems would also lower the detection limit and provide an opportunity for multiplexing, as well as testing for insertions/deletions/mutations in given sequences. However, longer RNA molecules, as is common in mRNA molecules or certain viruses, may require mechanical sheering or enzymatic cleavage prior to gel detection to allow effective gel penetration of the genetic material.
During gel electrophoresis, the relative mobility of migrating molecules depends on their size, conformation, and when running the samples in SDS-free conditions, their overall charge. It was found (
When the ability of gel electrophoresis to identify several mutations in the miRNA sequence was investigated (
As integrated systems for gel electrophoresis and visualization become more sensitive and affordable, the method introduced here could be an effective means for fast, specific, and sensitive identification of a variety of nucleic acid targets in point-of-care friendly settings.
The computer 1200 may have one or more input devices and/or output devices, such as output devices 1206 and input devices 1207 illustrated in
In the example of
While the above description has described various circuitry and methods for operating such circuitry in the context of ultrasound devices, the circuitry and methods may be used in the context of other electronic devices as well.
The indefinite articles “a” and “an,” as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean “at least one.”
The phrase “and/or,” as used herein in the specification and in the claims, should be understood to mean “either or both” of the elements so conjoined, i.e., elements that are conjunctively present in some cases and disjunctively present in other cases. Multiple elements listed with “and/or” should be construed in the same fashion, i.e., “one or more” of the elements so conjoined. Other elements may optionally be present other than the elements specifically identified by the “and/or” clause, whether related or unrelated to those elements specifically identified.
As used herein in the specification and in the claims, the phrase “at least one,” in reference to a list of one or more elements, should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements. This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase “at least one” refers, whether related or unrelated to those elements specifically identified.
Use of ordinal terms such as “first,” “second,” “third,” etc., in the claims to modify a claim element does not by itself connote any priority, precedence, or order of one claim element over another or the temporal order in which acts of a method are performed, but are used merely as labels to distinguish one claim element having a certain name from another element having a same name (but for use of the ordinal term) to distinguish the claim elements.
As used herein, reference to a numerical value being between two endpoints should be understood to encompass the situation in which the numerical value can assume either of the endpoints. For example, stating that a characteristic has a value between A and B, or between approximately A and B, should be understood to mean that the indicated range is inclusive of the endpoints A and B unless otherwise noted.
The terms “approximately” and “about” may be used to mean within +20% of a target value in some embodiments, within +10% of a target value in some embodiments, within +5% of a target value in some embodiments, and yet within +2% of a target value in some embodiments. The terms “approximately” and “about” may include the target value.
Also, the phraseology and terminology used herein is for the purpose of description and should not be regarded as limiting. The use of “including,” “comprising,” or “having,” “containing,” “involving,” and variations thereof herein, is meant to encompass the items listed thereafter and equivalents thereof as well as additional items.
Having described above several aspects of at least one embodiment, it is to be appreciated various alterations, modifications, and improvements will readily occur to those skilled in the art. Such alterations, modifications, and improvements are intended to be object of this disclosure. Accordingly, the foregoing description and drawings are by way of example only.
The present application claims the benefit under 35 U.S.C. § 119 (e) of U.S. Patent Application Ser. No. 63/142,348, filed Jan. 27, 2021 under Attorney Docket No. B0662.70113US00, and entitled “ELECTROPHORETIC MOBILITY SHIFT AS A MOLECULAR BEACON-BASED READOUT FOR miRNA DETECTION,” which is hereby incorporated by reference herein in its entirety.
This invention was made with Government support under RO1CA218500, UG3HL147353, and UG3TR002881 awarded by the National Institutes of Health. The Government has certain rights in the invention.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2022/014088 | 1/27/2022 | WO |
Number | Date | Country | |
---|---|---|---|
63142348 | Jan 2021 | US |